


BLENDING TEAM MEMBERS:

Greg Brigham, Ph.D. / CTN Ohio Valley Node
Beth Finnerty, M.P.H. / Pacific Southwest ATTC
Thomas Freese, Ph.D. / Pacific Southwest ATTC
Judith Harrer, Ph.D. / CTN Ohio Valley Node
Dennis McCarty, Ph.D. / CTN Oregon Node
Kay Gresham Morrison, LCSW, ACSW / Southeast ATTC
Susan Storti, Ph.D., R.N. / ATTC of New England

the BLENDING INITIATIVE

In order to disseminate information to the addiction treatment field, The National Institute on Drug Abuse (NIDA) has created a partnership with the Addiction Technology Transfer Center (ATTC) Network funded by the Center for Substance Abuse Treatment. The fourteen regional ATTCs and the ATTC National Office provide specialized training and technical assistance to substance abuse treatment professionals in order to create a more effective treatment workforce. Through the NIDA-SAMHSA Blending Initiative, special groups called Blending Teams-- comprised of NIDA researchers and ATTC representatives-- meet to design dissemination strategies. This Blending Team focused on treatment issues related to buprenorphine detoxification. The charge was to develop training materials for multidisciplinary (non-physician) addiction professionals based on the results of two NIDA CTN research studies: CTN 0001 and 0002. This training was designed to provide a broad overview of the two NIDA CTN studies and to provide instruction for the implementation of these research findings.



Short-Term Opioid Withdrawal Using Buprenorphine

FINDINGS *and* STRATEGIES

from A NIDA CLINICAL TRIALS

NETWORK STUDY*



*Actual titles are:

NIDA-CTN 0001: Buprenorphine-Naloxone
vs. Clonidine for Short-Term Inpatient
Opiate Detoxification

NIDA-CTN 0002: Buprenorphine-Naloxone
vs. Clonidine for Short-Term Outpatient
Opiate Detoxification





PREVALENCE

of OPIOID USE and ABUSE in the UNITED STATES

Opioid use and abuse continues to be a problem across the United States. In fact, research is showing the use is increasing.

- More than 3 million people over the age of 12 have used heroin at least one time.
- Between 1994 and 2001, the number of new heroin initiates was about 100,000 per year.
- Approximately 1.8% of Americans were currently using pain relievers and approximately 2 million people had used OxyContin at least once in their lives. The Drug Abuse Treatment Act of 2000 (DATA 2000) allows opioid treatment to continue as it has in the past, and it allows for expansion beyond the current structure to include treatment in office-based settings in addition to the traditional opioid treatment programs (OTPs).

By doing so:

- More patients may be willing to seek treatment;
- More patients will have access to treatment; and
- Stigma may be reduced by broadening the definition and locations of available treatment options Buprenorphine was approved by the FDA in 2002 as the first medication for treating opioid dependence available for use in office-based settings through implementation of DATA 2000 and through OTPs.

WHY FOCUS ON MEDICALLY-ASSISTED WITHDRAWAL (DETOXIFICATION)?

Little data have been generated for the shorter-term use of Buprenorphine/Naloxone for medically-assisted opioid withdrawal. However, studies are needed to determine strategies for assisting the withdrawal process. And the diversity of clinics in the NIDA Clinical Trials Network (CTN) provides an unparalleled opportunity to conduct such a clinical endeavor.

WHAT TYPE of PROGRAMS WERE INVOLVED in the STUDY and DO THEY RESEMBLE the 'REAL' WORLD of ADDICTIONS TREATMENT?

Community treatment programs were utilized for these two studies, and included a diverse range of programs, such as:

- Therapeutic communities
- Free-standing, chemical dependency hospitals
- Detoxification units with integrated addiction and mental health services
- Long term residential programs
- Opioid treatment programs
- Community mental health centers and
- A Managed Care Organization

WHAT WERE the OUTCOMES?

- The taper was successful in both outpatient and inpatient settings
- Buprenorphine/naloxone was superior to clonidine in both settings
- The inpatient setting had 76% of patients present and opioid negative (vs. 22% for clonidine patients)
- The outpatient setting had 29% of patients present and opioid negative (vs. 5% for clonidine patients)

EDUCATIONAL KIT INCLUDES:

TRAINER'S MANUAL CD-ROM
WITH POWERPOINT SLIDES

the TRAINING MANUAL ALSO PROVIDES:

Five quick steps to take to implement research findings in your program

Screening and assessment information


How to transfer patients to Buprenorphine/Naloxone

Administration information

Dosing schedules

Discussion of ancillary medications, and

Lessons Learned



**For more information visit
www.nattc.org**